Central Serous Chorioretinopathy Medication

Updated: Jun 18, 2019
  • Author: Kean Theng Oh, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print

Medication Summary

Currently, the use of mineralocorticoid antagonists such as aldosterone or eplerenone for the treatment of chronic and recurrent central serous chorioretinopathy (CSCR) is rising among retinal specialists worldwide. Eplerenone is administered at 25-50 mg orally each day. Multiple clinical trials have evaluated and supported the efficacy of mineralocorticoid antagonist use.  Coordination with the patient's primary care provider is recommended, and, in many instances, the primary care provider will substitute one of the patient's existing antihypertensive medications with the mineralocorticoid antagonist. Other case reports and series have evaluated a range of potential medical treatments for CSCR, such as rifampin. Currently, only case series and reports support the use of other medications.

Tatham and Macfarlane described a case series of patients who were treated with propranolol for CSCR. [53]  They suggested that beta-blockade had a hypothetical mechanism in treating CSCR. Further evidence is needed to substantiate this potential treatment.

Nielsen et al proposed the use of mifepristone in the treatment of chronic CSCR in a case report. [54]

Intravitreal bevacizumab (Avastin) has been used to successfully treat the rare complication of choroidal neovascularization following CSCR. [63, 64, 65]